A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Trial Profile

A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Hyponatraemia; Inappropriate antidiuretic hormone secretion
  • Focus Pharmacodynamics
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 22 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 May 2015 according to ClinicalTrials.gov record.
    • 07 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 May 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top